NanoViricides to Showcase NV-387's Potential at MicroCap Conference

NanoViricides, Inc. (NNVC) is set to present at the MicroCap Conference in Atlantic City, NJ, on Wednesday, January 29, 2025, at 11:00 AM. The company will discuss its lead drug candidate, NV-387, a broad-spectrum antiviral drug designed to combat Mpox disease, among other viral infections. This presentation offers an opportunity for investors to gain insights into the company's progress and the potential market applications of NV-387.



NV-387, a nanoviricide, targets viruses using a host-side feature, making it difficult for viruses to develop resistance. This innovative approach has shown promising preclinical results against a wide range of viruses, including RSV, influenza, and coronaviruses. The drug's broad-spectrum antiviral potential positions it as a vital tool for pandemic preparedness, addressing existing and future viral threats.

At the MicroCap Conference, NanoViricides is expected to provide updates on the upcoming Phase II clinical trial for NV-387, which is designed to assess its effectiveness in treating Severe Acute Respiratory Infections (SARI) caused by Influenza, RSV, and Coronaviruses. This trial is structured as an adaptive study, allowing for the simultaneous evaluation of NV-387 against multiple viral infections, streamlining the development process.

The company may also discuss the significant market potential for NV-387, given the unmet medical needs for effective antiviral therapies against RSV, Influenza, and emerging viral threats like Mpox. The pediatric RSV treatment market alone is projected to be worth billions of dollars annually in the United States, presenting a substantial opportunity for NanoViricides.



NanoViricides' strategic approach to regulatory approval, focusing on RSV in adults as a precursor to pediatric approval, and its collaborations with organizations like Karveer Meditech Pvt. Ltd., position the company to successfully navigate the complex global healthcare landscape. The presentation at the MicroCap Conference is an opportunity for investors to learn more about the company's progress and the potential of NV-387 in addressing emerging viral threats and the global healthcare landscape.

In conclusion, NanoViricides' presentation at the MicroCap Conference on January 29, 2025, is an exciting event for investors, as the company is expected to provide updates on its lead drug candidate, NV-387. The presentation offers insights into the drug's progress, market potential, and regulatory pathway, allowing investors to make informed decisions about the company's future prospects.